Odyssey outcomes - PVD results
Odyssey Outcomes: Addition of PCSK9i to Background Statin Therapy Further Reduces MACE.
Polyvascular Disease Sub-analysis Overview
Alirocumab in Patients with Polyvascular Disease and Recent Acute Coronary Syndrome
Objective
![](/.imaging/webp/sanofi-templates/w1080/dam/campus-sanofi-kw/Article-Images/images/jcr_content-(29).png/jcr:content/jcr_content%20(29).png)
In this prespecified analysis of the Odyssey Outcomes trial, we investigate the influence of polyvascular disease (PVD) on:
- Risks of MACE and death in patients with recent ACS and dyslipidemia despite intensive statin therapy
- The modification of risk by alirocumab
For the heterogeneity of alirocumab treatment effed by polyvascular disease category, Cox models were used for interaction terms for relative risk reduction and Gail-Simon tests for AR
Abbreviations
CeVD, cerebrovascular disease; PAD, peripheral artery disease
Primary MACE: One, two or three vascular beds
![](/dam/jcr:ca9c1d13-99b9-4e74-bbf3-2da8c84d39ab/jcr_content%20(3).png)
RRR interaction p=0.40. *In overall population, there were no differences in the incidence of adverse events or laboratory abnormalities between alirocumab and placebo groups, except for local injection-site reactions
Death: One, two or three vascular beds
![](/dam/jcr:758bff85-330d-4f9a-b86d-bd0196cf2265/jcr_content%20(8).webp)
HRs and p-values reflect stratification by geographic region
Polyvascular disease sub-analysis conclusions
- Increasing risk of death in patients with affected vascular beds remain a challenge for clinicians
- This study demonstrates that PVD is associated with high risk of death, and yet with alirocumab, the corresponding ARR for incidence of death was 0.4% (P-interaction = 0.002)
- Alirocumab, when added to high-intensity statin therapy, was associated with a reduction in mortality in this group of patients
Reference
- Jukema JW, et al. JACC. 2019; 74(9):1167-76.